Screening Study For Hepatitis B Shows Nearly 1/3 Also has Hepatitis D

The first US study which looked at hepatitis B (HBV) and hepatitis D (HDV) prevalence concurrently, found that nearly 1 in 3 (28%) HBV-positive specimens were also HDV-positive.¹ The study’s results were published in the Journal of Viral Hepatitis.

“We looked at over 5200 specimens across the US, about 2.2% of those were positive for hepatitis D antibodies,” said study first author Elizabeth Marlowe, PhD, D (ABMM), executive scientific director of Infectious Diseases for Quest Diagnostics. “Now the algorithm is if the antibody is positive, you then want to run a PCR to look for RNA, which means you have active infection. And of those, about 28% of those were positive for RNA.”

The study investigators looked at deidentified remnant HBsAg-positive specimens submitted for routine clinical testing to Quest, and represented all 10 Health and Human Services (HHS) regions. Females made up 45% of the participants and the mean ages were 50.8 (Male) and 49.4 (Female) years. Reflex testing of HBsAg-positive specimens for HDV antibody testing, and further testing of positive specimens for HDV RNA, were conducted from July 2023 to June 2024.¹

As the study looked at prevalence by HHS region, 1 interesting finding was the highest absolute number of HDV Ab-positive specimens in HHS region 9, which includes California, Nevada, Arizona).

HDV is concerning because of its ability to progress to more serious complications including cirrhosis and hepatocellular carcinoma. Wranke et al showed that having HDV leads to a faster progression to aforementioned conditions and other liver-related endpoints.²

“Given the serious nature of the disease, universal testing of HBsAg-positive specimens followed by reflex HDV RNA would increase our understanding of HDV prevalence, allow for earlier identification and linkage to care and benefit patients with previously unrecognized HDV infection,” the Journal of Viral Hepatitis investigators wrote.

Marlowe mentions updated screening guidelines that are expected to come out soon, and why in testing for HBV that HDV testing should be considered. She references Robert Gish, MD, who is the medical director of the Hepatitis B foundation and a fellow study author.

“He'll always tell you, if you have a hepatitis B surface antigen positive patient, always screen for hepatitis D,” Marlowe said.

Test and Treat

Traditionally, screening and getting treatment for hepatitis can take 2-3 provider visits. However, there is a newer concept within hepatitis C care called, “Test and Treat,” which looks to streamline the care process, and may be applicable to undetected chronic HBV and HDV patients. The concept simply has patients getting tested for the virus and leaving with medicine or a prescription for treatment all in the same appointment. The significance here is getting more people into the continuum of care.

“I think it's an exciting area," Marlowe said of test and treat. "I think it goes back to implementation science…And, we want to improve screening rates, so if you have a patient in the office, and you can screen them, and you're not going to lose them to follow up—that's the goal, right?”

References
1. Marlowe EM, Swanson BE, Realegeno SE, Meyer WA 3rd, Gish R, Kagan RM. Epidemiological Burden of Hepatitis Delta Virus in the United States. J Viral Hepat. 2025;32(6):e70029. doi:10.1111/jvh.70029
2. Wranke A, Heidrich B, Deterding K, et al. Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection. Hepatol Int. 2023;17(6):1359-1367. doi:10.1007/s12072-023-10575-0